New Jersey 2022-2023 Regular Session

New Jersey Senate Bill S301

Introduced
1/11/22  

Caption

Provides that purchase of insulin is not subject to deductible and requires health insurers to limit copayments and coinsurance for insulin.

Impact

This bill will have a significant impact on state laws regarding health insurance coverage, specifically those regulating health benefits plans for individuals and small employers. By mandating that plans provide insulin coverage free from deductibles and imposing limits on copayments, the bill aims to reduce unnecessary healthcare expenditure and ensure better access to diabetes management resources. Additionally, it emphasizes the need for transparency in pricing from drug manufacturers, addressing long-standing concerns about the lack of competition and accountability in the insulin market, which have contributed to skyrocketing prices over time.

Summary

Senate Bill S301 addresses the escalating costs of insulin by mandating health insurers in New Jersey to provide coverage for insulin purchases without subjecting them to deductibles. It also limits the maximum copayment or coinsurance for insulin to $50 per 30-day supply, thereby directly alleviating the financial burden on diabetes patients who rely on this essential medication. The legislation's primary aim is to ensure that individuals with diabetes have access to necessary treatments without facing exorbitant out-of-pocket costs that can jeopardize their health and financial stability.

Contention

While S301 is primarily framed as a consumer protection measure, there are potential points of contention. Some stakeholders may argue that the bill could lead to increased insurance premiums as insurers adapt to these mandated coverage requirements. Additionally, concerns may arise over the bill's implications for the broader pharmaceutical market, particularly regarding how it interacts with existing incentive structures for generic insulin production and pricing practices among manufacturers. Critics may also point out that while limiting costs is beneficial, there are systemic issues within healthcare financing that require more extensive reforms to yield sustainable benefits.

Companion Bills

NJ A553

Same As Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.

Similar Bills

NJ A1439

Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.

NJ A553

Provides that purchase of insulin is not subject to deductible; requires health insurers to limit copayments and coinsurance for insulin; requires insulin manufacturers to submit report to Commissioner of Banking and Insurance.

NJ A2839

Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.

NJ S1614

Requires health insurance carriers to provide coverage for epinephrine auto-injector devices and asthma inhalers; limits cost sharing for health insurance coverage of insulin.

NJ A4627

Requires DOH to maintain emergency stockpile of insulin and authorizes dispensing of emergency supply of insulin to certain patients.

NJ S1820

Requires DOH to maintain emergency stockpile of insulin and authorizes dispensing of emergency supply of insulin to certain patients.

NJ A3571

Requires DOH to maintain emergency stockpile of insulin and authorizes dispensing of emergency supply of insulin to certain patients.

NJ S945

Requires Medicaid coverage for self-administered hormonal contraceptives dispensed by pharmacist under standing order.